Drugs / DCBCI0901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02151357 | Aug 2014 → Jun 2016 | cancer | Standard Chem. & Pharm. Co., Ltd. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-04-22 | Intech Biopharm Ltd. | Regulatory 益得生技參與之「DCBCI0901」mTOR抑制劑抗癌標靶新藥，獲准進入第一期臨床試驗 intechbiopharm.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-04-22 | Intech Biopharm Ltd. | 益得生技參與之「DCBCI0901」mTOR抑制劑抗癌標靶新藥，獲准進入第一期臨床試驗 intechbiopharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCBCI0901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02151357 ↗ |
| Route | Intravenous | “DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20” NCT02151357 ↗ |